(Oncodesign) Novel PSMA+ and FAP+ mouse models to support the development of novel molecular radiotherapy agents

New radiotherapy development with genO-BRGSF

May 21, 2025

Abstract

  • Robust preclinical models are required for the evaluation of novel PSMA-overexpressing mouse models molecular radiotherapies (MRT):
    • accuratelymimicking human tumor microenvironments
    • Expressing optimal levels of target proteins.
  • Tow biomarkers of interest in the field of MRT and Oncology are:

1. Fibroblast activation protein (FAP): Minimally expressed in regular tissues, upregulated in cancer-associated fibroblasts within the tumor microenvironment.

2. Prostate-specific membrane antigen (PSMA): overexpressed in most prostate cancers.

  • Oncodesign Services already had PSMA-overexpressing models available, but only on Balb/c Nude mice. This strain is radiosensitve due to a mutation and has become unavailable for purchase in the recent months.
  • Furthermore, inherently expressing FAP models are available, but have minimal FAP-expression.
  • To close the gap in our catalogue, Oncodesign Services has recently developed novel FAP and PSMA-overexpressing models in nonradiosensitve mouse strains.

Related products

Catalogue product

genO‑BRGSF

The genO-BRGSF mouse is the most immunodeficient model developed so far, relative to strains like NOD-SCID and NSG.

Customized product

No items found.
Related posters
No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe